Pharmaceutical composition for preventing or treating obesity, comprising black rice bran bioconversion product as active ingredient

Abstract

Obesity can be involved in or cause the worsening of various diseases such as hypertension, arteriosclerosis, fatty liver and diabetes, and thus it is important to prevent obesity. With respect to obesity, it is very important for the prevention of various diseases and for health that body metabolism is regulated to occur smoothly through a reduction in body fat. The present invention relates to a pharmaceutical composition for preventing or treating obesity, comprising, as an active ingredient, a black rice bran bioconversion product prepared by fermenting black rice bran with basidiomycete mycelium. The black rice bran bioconversion product of the present invention is a natural food-derived material, is harmless to the human body, and has excellent anti-obesity effects. Therefore, the black rice bran bioconversion product of the present invention is a composition that can be administered alone or in combination with other natural food-derived substances, and is expected to be widely used in the fields of health, medicine and food.

Description

Pharmaceutical composition for preventing or treating obesity containing black rice biotransformation product as an active ingredient

[0001] The present invention relates to a pharmaceutical composition for preventing or treating obesity, which comprises a black rice bioconversion product as an active ingredient.

[0002]

[0003] In Korea, the number of obese people has been increasing significantly due to Westernized eating habits and improved cultural standards. Obesity can contribute to or exacerbate various diseases, including hypertension, arteriosclerosis, fatty liver disease, and diabetes, so prevention is crucial. If you're already obese, reducing body fat and regulating your metabolism is crucial for disease prevention and overall health. Therefore, various diet products are available on the market to prevent and treat obesity, including those containing dietary fiber, dairy proteins, and herbal medicines. A variety of diet drinks are also available. However, the development of safe, long-term, natural food compositions that deliver significant weight loss effects remains limited.

[0004] Meanwhile, the present invention relates to a pharmaceutical composition for the prevention or treatment of obesity, which comprises as an active ingredient a black rice bran bioconversion product manufactured by fermenting black rice bran with basidiomycete mycelia. The black rice bran bioconversion product of the present invention is a natural food-derived substance, harmless to the human body, and has been shown to have excellent anti-obesity efficacy. Therefore, the black rice bran bioconversion product of the present invention is a composition that can be administered alone or in combination with other natural food-derived substances, and is expected to be widely utilized in the health, medical, and food fields.

[0005]

[0006] The present invention was conceived to address the aforementioned technical problems of the prior art, and relates to a pharmaceutical composition for the prevention or treatment of obesity, comprising a black rice biotransformation product as an active ingredient. However, the technical challenges posed by the present invention are not limited to those mentioned above, and other unmentioned challenges will be readily apparent to those skilled in the art from the description below.

[0007] Therefore, one object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity containing a black rice bioconversion product as an active ingredient.

[0008] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity, which comprises a black rice bioconversion product as an active ingredient and additionally comprises a mustard extract or a green tea extract as an active ingredient.

[0009]

[0010] Hereinafter, various embodiments described herein will be described with reference to the drawings. In the following description, various specific details, such as specific configurations, compositions, and processes, are set forth to provide a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or in conjunction with other known methods and configurations. In other instances, well-known processes and manufacturing techniques have not been described in specific detail so as not to unnecessarily obscure the present invention. Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the present invention. Thus, the appearances of "in one embodiment" or "an embodiment" in various places throughout this specification do not necessarily refer to the same embodiment of the present invention. Additionally, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.

[0011] Unless otherwise specifically defined herein, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.

[0012]

[0013] In the present invention, obesity refers to a state in which abnormal or excessive fat is accumulated in adipose tissue to the extent that it is detrimental to health. The criteria for obesity differ between the West and Asia. In Asians, there are many reports that the risk of metabolic syndrome complications such as hypertension and diabetes begins to increase from a body mass index (BMI) of 25 or lower, so the BMI used to define obesity is lower than in the West. In Korea, a body mass index (BMI) of 25-29.9 is defined as overweight, and a BMI of 30 or higher is defined as obesity. However, even if a person appears thin and has a normal weight, if their body fat percentage is higher than normal, they may be medically diagnosed as obesity, or skinny fat. In the present invention, obesity includes skinny fat.

[0014]

[0015] In the present invention, black rice (Oryza sativa L.) is a type of rice that contains a lot of functional ingredients such as anthocyanins and polyphenols. Black rice contains starch, protein, fatty acids, etc. as nutrients, and in addition to the anthocyanins and polyphenols described above, it also contains fiber, essential minerals, vitamin B complex, vitamin C, niacin, carotene, etc., so it is often consumed as a cooked rice by mixing a small amount with white rice as a health food rather than a food. The medicinal effects of black rice are known to include antioxidant, anticancer, anti-inflammatory, and antihyperlipidemic effects due to anthocyanins, etc., and recently, it has been processed and developed into a functional food.

[0016] In this specification, black rice bran refers to a by-product including the outer hull and a small amount of bran layer removed during the polishing or milling of black rice.

[0017]

[0018] In the present invention, Basidiomycota is a subphylum of fungi that is a fungus that produces spores by forming cells called basidia as a result of sexual reproduction. Since they cannot produce their own nutrients, they attach themselves to other organisms and live as parasites. Many of them are known as mushrooms, such as shiitake mushrooms, sang-hwang mushrooms, chaga mushrooms, maitake mushrooms, oyster mushrooms, pine mushrooms, and chive mushrooms are representative. Basidiomycota are densely formed on the cap wrinkles of mature mushrooms. Most basidiomycota mushrooms live as saprophytes in the fluids of higher plants, and play an essential role in the biological cycle of substances by decomposing cellulose and lignin. However, many also form mycorrhizae on the roots of trees and live communally. In addition, there are some species that are considered important as edible fungi or that require caution as poisonous mushrooms.

[0019]

[0020] In the present invention, hyphae are vegetative cells of filamentous fungi (molds). Functional differentiation, such as nutritional and physiological functions, can also be observed. Morphologically, the presence or absence of septa is used for classification, and they develop from the germ tube of spores and extend by apical growth. A group of branched hyphae is called a mycelium. Depending on physiological function, they are distinguished as basal hyphae, which extend by entering the surface or interior of a medium or host, and parasitic hyphae, which extend in the air. Parasitic hyphae depend on the transport of nutrients from basal hyphae, and some of them differentiate into spore-forming organs, etc. In favorable environmental conditions, such as the presence of organic matter and appropriate humidity and temperature, they form various mycelial structures. The septa of ascomycetes are simple, but in basidiomycetes, they often form clamp connections. In fungi, they branch into multiple branches and are tangled like threads, and in mushrooms, they gather to form fruiting bodies. They lack chlorophyll and cannot photosynthesize, so they attach to host organisms to absorb nutrients. In the case of basidiomycetes, which are mushrooms, the hyphae that sprout from spores have one nucleus, and when this fuses with another hyphae, each cell ends up with two nuclei. Hyphae with one nucleus are called primary hyphae, and hyphae with two nuclei are called secondary hyphae. In this specification, the basidiomycete mycelia may be selected from the mycelia of medicinal and edible basidiomycetes such as shiitake mushrooms, sang-hwang mushrooms, chaga mushrooms, maitake mushrooms, oyster mushrooms, snow mushrooms, and chive mushrooms, and these basidiomycete mycelia may be used by receiving strains from institutions such as the Korea Center for Microorganism Conservation (KCCM), the Korea Center for Biotechnology and Bioscience and Biotechnology (KCTC), the Korea Cell Line Bank (KCLB), the Korea Agricultural Microbial Resource Center (KACC), and the American Type Culture Collection (ATCC).

[0021]

[0022] In the present invention, bioconversion refers to inducing a structural change in an added substance through a biological method such as fermentation or enzyme treatment, thereby converting it into a chemically modified form and inducing the production of a new component.

[0023]

[0024] In the present invention, fermentation refers to the process in which microorganisms decompose organic matter using the enzymes they possess. Fermentation is a phenomenon in which organic matter is transformed into simple compounds by enzyme action and releases free energy, but generally refers to a phenomenon in which microorganisms accumulate metabolites through the decomposition process of organic matter. That is, typical fermentations include alcohol fermentation, in which yeast anaerobically decomposes sugar into ethyl alcohol and carbon dioxide, and lactic acid fermentation, in which lactic acid bacteria anaerobically decompose sugar into lactic acid. However, currently, the phenomenon in which acetic acid bacteria oxidize alcohol into acetic acid using oxygen in the air, and the phenomenon in which molds oxidize glucose into gluconic acid using oxygen in the air, are also called acetic acid fermentation and gluconic acid fermentation, respectively. Also, these are divided into anaerobic fermentation and aerobic fermentation (oxidative fermentation) and discussed, and anaerobic fermentation other than those mentioned above includes glycerol fermentation, acetonebutanol fermentation, 2, 3-butylene glycol fermentation, butyric acid fermentation, propionic acid fermentation, methane fermentation, etc., and aerobic fermentation includes citric acid fermentation, itaconic acid fermentation, succinic acid fermentation, 2-ketoglutarate fermentation, oxalic acid fermentation, fumaric acid fermentation, sorbose fermentation, etc. In addition, the production of amino acids, vitamins, and antibiotics by microorganisms is also called, for example, glutamic acid fermentation, riboflavin fermentation, and penicillin fermentation, but these are not very good names. In principle, the name of the fermentation process is called by the product, but sometimes the name of the substrate is added, such as cellulose fermentation or pectin fermentation.

[0025]

[0026] In the present invention, the extract refers to an active ingredient separated from a natural product, and for example, refers to a preparation obtained by squeezing a natural product with an appropriate solvent, filtering it, and then evaporating the solvent to concentrate it. In addition, it may be an extract obtained by extraction treatment, a diluted or concentrated extract, a dried product obtained by drying the extract, or a purified product thereof, but is not limited thereto. The extraction method is not limited thereto, but may be obtained by an extraction method selected from the group consisting of a solvent extraction method, an ultrasonic extraction method, a supercritical extraction method, a hot water extraction method, a high-frequency extraction method, a fermentation method, and a formulation method, and is preferably a hot water extraction method or a high-frequency extraction method, but is not limited thereto. At this time, the high-frequency extraction may be performed at a frequency of 100 to 3000 kHz, 300 to 2000 kHz, or 700 to 1200 kHz, or may be performed at a power of 100 to 1000 W, 200 to 800 W, 300 to 600 W, or 100 to 400 W. The hot water extraction may be performed at 10 to 95°C, 20 to 75°C, or room temperature for 2 to 96 hours, 6 to 48 hours, 12 to 36 hours, or 4 to 12 hours, and the high-frequency extraction may be performed at 20 to 30°C, 22 to 26°C, or room temperature for 1 to 12 hours, 1 to 8 hours, 2 to 6 hours, or 2 to 4 hours. When using the above hot water extraction method or high-frequency extraction method, the solvent may be selected from the group consisting of water, ethanol, organic solvents, and mixed solvents thereof. Preferably, it may be purified water, ethanol, or a mixed solvent thereof, but is not limited thereto.

[0027]

[0028] In one specific embodiment of the present invention, the pharmaceutical composition refers to a composition administered for a specific purpose. For the purpose of the present invention, the pharmaceutical composition of the present invention is intended to prevent or treat obesity, and may additionally include an acceptable carrier, excipient, or diluent in addition to the active ingredient of the present invention involved therein. In addition, the pharmaceutical composition according to the present invention comprises the active ingredient of the present invention in an amount of 0.1 to 50 wt% based on the total weight of the composition. Carriers, excipients and diluents that may be included in the composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

[0029] Specifically, the pharmaceutical composition for preventing and treating obesity of the present invention preferably comprises a black rice biotransformation product and may additionally comprise mustard extract or green tea extract. Preferably, it comprises a black rice biotransformation product and a green tea extract, but is not limited thereto.

[0030] The above pharmaceutically acceptable salts should have low toxicity to the human body and should not adversely affect the biological activity and physicochemical properties of the parent compound. Pharmaceutically acceptable salts include, but are not limited to, acid addition salts of pharmaceutically acceptable free acids and base compounds. Preferred salt forms include salts with inorganic acids or organic acids. In this case, inorganic acids that can be used include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, and hydrobromic acid. In addition, organic acids that can be used include acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, oxalic acid, benzoic acid, embonic acid, aspartic acid, and glutamic acid. Organic bases that can be used to prepare organic base addition salts include tris(hydroxymethyl)methylamine and dicyclohexylamine. Amino acids that can be used to prepare amino acid addition salts include naturally occurring amino acids such as alanine and glycine. It will be apparent to those skilled in the art that other acids or bases may be used in addition to the inorganic acids, organic acids, organic bases, and amino acids exemplified above. Furthermore, the salts can be prepared by conventional methods.

[0031] Meanwhile, in the present invention, prevention may include, without limitation, any act of blocking, suppressing, or delaying symptoms caused by obesity by using the pharmaceutical composition of the present invention.

[0032] Additionally, in the present invention, treatment may include, without limitation, any action that improves or benefits symptoms caused by obesity by using the pharmaceutical composition of the present invention.

[0033] In addition, in the present invention, administration means introducing the composition of the present invention into a patient by any appropriate method, and the route of administration of the composition of the present invention may be administered through any general route as long as it can reach the target tissue. Specifically, it may be administered in the form of oral administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, intranasal administration, intrapulmonary administration, rectal administration, intracavitary administration, intraperitoneal administration, intrathecal administration, or intraocular administration, but is not limited thereto. In the present invention, the effective amount may be adjusted according to various factors including the type of disease, the severity of the disease, the type and content of the active ingredient and other ingredients contained in the composition, the type of formulation, and the patient's age, body weight, general health condition, sex, and diet, the time of administration, the route of administration, and the secretion rate of the composition, the treatment period, and concurrently used drugs.

[0034] In the present invention, the pharmaceutical composition may be characterized as being in the form of a capsule, tablet, granule, injection, ointment, powder, gel, gel, or beverage, and the pharmaceutical composition may be characterized as being preferably intended for animals, more preferably mammals, and most preferably humans.

[0035]

[0036] In one specific embodiment of the present invention, the food composition is used in various ways to prevent or improve the indications targeted in the present invention, and for the purpose of the present invention, the food composition of the present invention is for preventing or improving obesity. The food composition including the active ingredient of the present invention can be manufactured in the form of various foods, for example, beverages, gum, tea, vitamin complexes, powders, granules, tablets, capsules, jellies, gels, confectionery, rice cakes, bread, etc. Since the food composition of the present invention is improved and composed from natural foods with almost no toxicity or side effects, it can be used with confidence even when taken for a long period of time for preventive purposes. When the composition of the present invention is included in a food composition, the amount can be added at a ratio of 0.1 to 100% of the total weight. Here, when the food composition is manufactured in the form of a beverage, there is no special limitation other than containing the food composition at the indicated ratio, and various flavoring agents or natural carbohydrates, etc., can be contained as additional ingredients like conventional beverages. That is, it may include natural carbohydrates such as monosaccharides such as glucose, disaccharides such as fructose and sucrose, polysaccharides, common polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agent (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agent (saccharin, aspartame, etc.) can be mentioned. In addition, the food composition of the present invention can contain various nutrients, vitamins, minerals (electrolytes), flavoring agent such as synthetic flavoring agent and natural flavoring agent, coloring agent, pectic acid and its salt, alginic acid and its salt, organic acid, protective colloid thickener, pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonating agent used in carbonated beverage, etc. These components can be used independently or in combination. The ratio of such additives is typically 0.It is generally selected from the range of 1 to 100 parts by weight, but is not limited thereto.

[0037]

[0038] In this specification, the cosmetic composition is used in various ways to prevent or improve the indications targeted in the present invention, and for the purpose of the present invention, the cosmetic composition of the present invention is for preventing or improving obesity. A cosmetic composition comprising the composition of the present invention as an active ingredient may be manufactured in the form of a toner, a nutritional lotion, a nutritional essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, a baby powder, a shower gel, a shower cream, a sunscreen lotion, a sunscreen cream, a suntan cream, a skin lotion, a skin cream, a UV-blocking cosmetic, a cleansing milk, a depilatory agent {for cosmetic use}, a face and body lotion, a face and body cream, a skin whitening cream, a hand lotion, a hair lotion, a cosmetic cream, jasmine oil, a bath soap, a liquid soap, a beauty soap, a shampoo, a hand cleanser (hand cleaner), a medicated soap {for non-medical use}, a cream soap, a facial wash, a hair rinse, a cosmetic soap, a tooth whitening gel, a toothpaste, etc. To this end, the composition of the present invention may further comprise an appropriate carrier, excipient, or diluent commonly used in the manufacture of a cosmetic composition. Carriers, excipients or diluents that may be further added to the cosmetic composition of the present invention include, but are not limited to, purified water, oils, waxes, fatty acids, fatty alcohols, fatty acid esters, surfactants, humectants, thickeners, antioxidants, viscosity stabilizers, chelating agents, buffers, lower alcohols, etc. In addition, whitening agents, moisturizers, vitamins, sunscreens, perfumes, dyes, antibiotics, antibacterial agents, and antifungal agents may be included as needed. Examples of the oils that may be used include hydrogenated vegetable oils, castor oil, cottonseed oil, olive oil, palm kernel oil, jojoba oil, and avocado oil, and examples of the waxes that may be used include beeswax, spermaceti, carnauba, candelilla, montan, ceresin, liquid paraffin, and lanolin.As fatty acids, stearic acid, linoleic acid, linolenic acid, and oleic acid can be used; as fatty acid alcohols, cetyl alcohol, octyldodecanol, oleyl alcohol, panthenol, lanolin alcohol, stearyl alcohol, and hexadecanol can be used; and as fatty acid esters, isopropyl myristate, isopropyl palmitate, and butyl stearate can be used. As surfactants, cationic surfactants, anionic surfactants, and nonionic surfactants known in the art can be used, and surfactants derived from natural products are preferable if possible. In addition, absorbents, thickeners, and antioxidants widely known in the cosmetics field can be included, and the types and amounts of these are as known in the art.

[0039]

[0040] According to one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating obesity, which comprises as an active ingredient a bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia. The bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia is prepared by: (a) converting black rice bran into a liquid culture medium; (b) inoculating basidiomycete mycelia into the liquid black rice bran medium converted into a culture medium in step (a) and culturing and fermenting it; And, (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme; may be manufactured by a method including; wherein the basidiomycete mycelia may be any one or more mycelia selected from the group consisting of shiitake mushrooms, Phellinus linteus, Chaga mushrooms, Maitake mushrooms, Wood ear mushrooms, Snow mushrooms, and Schizo mushrooms, and the cellulolytic enzyme may be any one or more selected from the group consisting of cellulase, hemicellulase, pectinase, and glucanase, but is not limited thereto. The bioconversion product fermented with the black rice bran with the basidiomycete mycelia may be manufactured as a solid-liquid separation fraction of the black rice bran bioconversion product by a method additionally including, in addition to steps (a) to (c), (d) a step of removing insoluble residues from the fermented product of step (c).

[0041] The pharmaceutical composition for preventing or treating obesity, which comprises as an active ingredient a bioconversion product obtained by fermenting the black rice bran of the present invention with basidiomycete mycelia, may additionally comprise mustard extract or green tea extract, and the extract may be a hot water extract or a high-frequency extract.

[0042]

[0043] According to another aspect of the present invention, the present invention provides a food composition for preventing or improving obesity, which comprises as an active ingredient a bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia. The bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia is prepared by: (a) converting black rice bran into a liquid culture medium; (b) inoculating basidiomycete mycelia into the liquid black rice bran medium converted into a culture medium in step (a) and performing culture and fermentation; And, (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme; may be manufactured by a method including; wherein the basidiomycete mycelia may be any one or more mycelia selected from the group consisting of shiitake mushrooms, Phellinus linteus, Chaga mushrooms, Maitake mushrooms, Wood ear mushrooms, Snow mushrooms, and Schizo mushrooms, and the cellulolytic enzyme may be any one or more selected from the group consisting of cellulase, hemicellulase, pectinase, and glucanase, but is not limited thereto. The bioconversion product fermented with the black rice bran with the basidiomycete mycelia may be manufactured as a solid-liquid separation fraction of the black rice bran bioconversion product by a method additionally including, in addition to steps (a) to (c), (d) a step of removing insoluble residues from the fermented product of step (c).

[0044] The food composition for preventing or improving obesity, which comprises as an active ingredient a bioconversion product obtained by fermenting the black rice bran of the present invention with basidiomycete mycelia, may additionally comprise mustard extract or green tea extract, and the extract may be a hot water extract or a high-frequency extract.

[0045] In addition, a food composition for preventing or improving obesity, which contains as an active ingredient a bioconversion product obtained by fermenting the black rice bran with basidiomycete mycelia, may be manufactured in the form of a beverage, gum, tea, vitamin complex, powder, granules, tablets, capsules, jelly, gel, confectionery, rice cake, or bread.

[0046]

[0047] According to another aspect of the present invention, the present invention provides a cosmetic composition for preventing or improving obesity, which comprises as an active ingredient a bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia. The bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia is prepared by: (a) converting black rice bran into a liquid culture medium; (b) inoculating basidiomycete mycelia into the liquid black rice bran medium converted into a culture medium in step (a) and culturing and fermenting it; And, (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme; may be manufactured by a method including; wherein the basidiomycete mycelia may be any one or more mycelia selected from the group consisting of shiitake mushrooms, Phellinus linteus, Chaga mushrooms, Maitake mushrooms, Wood ear mushrooms, Snow mushrooms, and Schizo mushrooms, and the cellulolytic enzyme may be any one or more selected from the group consisting of cellulase, hemicellulase, pectinase, and glucanase, but is not limited thereto. The bioconversion product fermented with the black rice bran with the basidiomycete mycelia may be manufactured as a solid-liquid separation fraction of the black rice bran bioconversion product by a method additionally including, in addition to steps (a) to (c), (d) a step of removing insoluble residues from the fermented product of step (c).

[0048] The cosmetic composition for preventing or improving obesity, which comprises as an active ingredient a bioconversion product obtained by fermenting the black rice bran of the present invention with basidiomycete mycelia, may additionally comprise mustard extract or green tea extract, and the extract may be a hot water extract or a high-frequency extract.

[0049] In addition, a cosmetic composition for preventing or improving obesity, which contains as an active ingredient a bioconversion product obtained by fermenting the black rice bran with basidiomycete mycelia, may be manufactured in the form of a toner, a nutritional lotion, a nutritional essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, a baby powder, a shower gel, a shower cream, a sunscreen lotion, a sunscreen cream, a suntan cream, a skin lotion, a skin cream, a UV-blocking cosmetic, a cleansing milk, a hair loss agent {for cosmetic use}, a face and body lotion, a face and body cream, a skin whitening cream, a hand lotion, a hair lotion, a cosmetic cream, jasmine oil, a bath soap, a liquid soap, a beauty soap, a shampoo, a hand sanitizer, a medicated soap {for non-medical use}, a cream soap, a facial wash, a hair rinse, a cosmetic soap, a tooth whitening gel, or a toothpaste.

[0050]

[0051] According to another aspect of the present invention, the present invention provides a method for preparing a pharmaceutical composition for preventing or treating obesity, comprising the steps of (a) preparing a solid-liquid separation fraction of a black rice bran bioconversion product; and (b) mixing (a) with a mustard extract or a green tea extract.

[0052] The above black rice bran bioconversion product may be manufactured by a method including: (a) a step of converting black rice bran into a liquid culture medium; (b) a step of inoculating basidiomycete mycelia into the liquid black rice bran culture medium of step (a) and performing culture fermentation; and, (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme. Here, the basidiomycete mycelia may be any one or more mycelia selected from the group consisting of shiitake mushrooms, pine mushrooms, chaga mushrooms, maitake mushrooms, oyster mushrooms, snow mushrooms, and chive mushrooms, and the cellulolytic enzyme may be any one or more selected from the group consisting of cellulase, hemicellulase, pectinase, and glucanase, but is not limited thereto. The above black rice bioconversion product may be manufactured by a method that additionally includes, in addition to steps (a) to (c), a step (d) of removing insoluble residue from the fermented product of step (c).

[0053] The above-mentioned mustard leaf extract or green tea extract may be a hot water extract or a high-frequency extract using mustard leaf or green tea as a raw material. The high-frequency extraction may be performed at a frequency of 100 to 3000 kHz, 300 to 2000 kHz, or 700 to 1200 kHz, or may be performed at a power of 100 to 1000 W, 200 to 800 W, 300 to 600 W, or 100 to 400 W. The hot water extraction may be performed at 10 to 95°C, 20 to 75°C, or room temperature for 2 to 96 hours, 6 to 48 hours, 12 to 36 hours, or 4 to 12 hours, and the high-frequency extraction may be performed at 20 to 30°C, 22 to 26°C, or room temperature for 1 to 12 hours, 1 to 8 hours, 2 to 6 hours, or 2 to 4 hours. When the hot water extraction method or the high-frequency extraction method is used, the solvent may be selected from the group consisting of water, ethanol, an organic solvent, and a mixed solvent thereof. Preferably, it may be purified water, butylene glycol, or a mixed solvent thereof, but is not limited thereto.

[0054]

[0055] According to another aspect of the present invention, the present invention provides a method for producing a food composition for preventing or improving obesity, comprising the steps of (a) producing a solid-liquid separation fraction of a black rice bioconversion product; and (b) mixing (a) with a mustard extract or a green tea extract.

[0056] The above black rice bran bioconversion product may be manufactured by a method including: (a) a step of converting black rice bran into a liquid culture medium; (b) a step of inoculating basidiomycete mycelia into the liquid black rice bran culture medium of step (a) and performing culture fermentation; and, (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme. Here, the basidiomycete mycelia may be any one or more mycelia selected from the group consisting of shiitake mushrooms, pine mushrooms, chaga mushrooms, maitake mushrooms, oyster mushrooms, snow mushrooms, and chive mushrooms, and the cellulolytic enzyme may be any one or more selected from the group consisting of cellulase, hemicellulase, pectinase, and glucanase, but is not limited thereto. The above black rice bioconversion product may be manufactured by a method that additionally includes, in addition to steps (a) to (c), a step (d) of removing insoluble residue from the fermented product of step (c).

[0057] The above-mentioned mustard leaf extract or green tea extract may be a hot water extract or a high-frequency extract using mustard leaf or green tea as a raw material. The high-frequency extraction may be performed at a frequency of 100 to 3000 kHz, 300 to 2000 kHz, or 700 to 1200 kHz, or may be performed at a power of 100 to 1000 W, 200 to 800 W, 300 to 600 W, or 100 to 400 W. The hot water extraction may be performed at 10 to 95°C, 20 to 75°C, or room temperature for 2 to 96 hours, 6 to 48 hours, 12 to 36 hours, or 4 to 12 hours, and the high-frequency extraction may be performed at 20 to 30°C, 22 to 26°C, or room temperature for 1 to 12 hours, 1 to 8 hours, 2 to 6 hours, or 2 to 4 hours. When the hot water extraction method or the high-frequency extraction method is used, the solvent may be selected from the group consisting of water, ethanol, an organic solvent, and a mixed solvent thereof. Preferably, it may be purified water, butylene glycol, or a mixed solvent thereof, but is not limited thereto.

[0058] In addition, the above manufacturing method may be used to manufacture a food composition for preventing or improving obesity, which includes a bioconversion product fermented from black rice bran with basidiomycete mycelia as an active ingredient, in the form of a beverage, gum, tea, vitamin complex, powder, granules, tablets, capsules, jellies, gels, confectionery, rice cakes, or bread.

[0059]

[0060] According to another aspect of the present invention, the present invention provides a method for preparing a cosmetic composition for preventing or improving obesity, comprising the steps of (a) preparing a solid-liquid separation fraction of a black rice bioconversion product; and (b) mixing (a) with a mustard extract or a green tea extract.

[0061] The above black rice bran bioconversion product may be manufactured by a method including: (a) a step of converting black rice bran into a liquid culture medium; (b) a step of inoculating basidiomycete mycelia into the liquid black rice bran culture medium of step (a) and performing culture fermentation; and, (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme. Here, the basidiomycete mycelia may be any one or more mycelia selected from the group consisting of shiitake mushrooms, pine mushrooms, chaga mushrooms, maitake mushrooms, oyster mushrooms, snow mushrooms, and chive mushrooms, and the cellulolytic enzyme may be any one or more selected from the group consisting of cellulase, hemicellulase, pectinase, and glucanase, but is not limited thereto. The above black rice bioconversion product may be manufactured by a method that additionally includes, in addition to steps (a) to (c), a step (d) of removing insoluble residue from the fermented product of step (c).

[0062] The above-mentioned mustard leaf extract or green tea extract may be a hot water extract or a high-frequency extract using mustard leaf or green tea as a raw material. The high-frequency extraction may be performed at a frequency of 100 to 3000 kHz, 300 to 2000 kHz, or 700 to 1200 kHz, or may be performed at a power of 100 to 1000 W, 200 to 800 W, 300 to 600 W, or 100 to 400 W. The hot water extraction may be performed at 10 to 85°C, 20 to 75°C, or room temperature for 2 to 96 hours, 6 to 48 hours, 12 to 36 hours, or 4 to 12 hours, and the high-frequency extraction may be performed at 20 to 30°C, 22 to 26°C, or room temperature for 1 to 12 hours, 1 to 8 hours, 2 to 6 hours, or 2 to 4 hours. When the hot water extraction method or the high-frequency extraction method is used, the solvent may be selected from the group consisting of water, ethanol, an organic solvent, and a mixed solvent thereof. Preferably, it may be purified water, butylene glycol, or a mixed solvent thereof, but is not limited thereto.

[0063] In addition, the above manufacturing method may be a method of manufacturing a cosmetic composition for preventing or improving obesity, which contains as an active ingredient a bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia, in the form of a toner, a nutritional lotion, a nutritional essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, a baby powder, a shower gel, a shower cream, a sunscreen lotion, a sunscreen cream, a suntan cream, a skin lotion, a skin cream, a UV-blocking cosmetic, a cleansing milk, a hair loss agent {for cosmetic use}, a face and body lotion, a face and body cream, a skin whitening cream, a hand lotion, a hair lotion, a cosmetic cream, jasmine oil, a bath soap, a liquid soap, a beauty soap, a shampoo, a hand sanitizer, a medicated soap {for non-medical use}, a cream soap, a facial wash, a hair rinse, a cosmetic soap, a tooth whitening gel, or a toothpaste.

[0064]

[0065] According to another aspect of the present invention, the present invention provides a method for preventing or treating obesity, comprising the step of administering to a subject in need of treatment a pharmaceutical composition comprising a bioconversion product of black rice bran fermented with basidiomycete mycelia.

[0066] An individual requiring the above treatment is an individual with abnormal or excessive fat accumulation in adipose tissue to the extent that it is detrimental to health.

[0067] The above-mentioned black rice bran bioconversion product fermented with basidiomycete mycelia is a bioconversion product manufactured by a method including: (a) a step of converting black rice bran into a liquid culture medium; (b) a step of inoculating basidiomycete mycelia into the liquid black rice bran culture medium of step (a) and performing culture fermentation; and (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme.

[0068] The pharmaceutical composition administered for the prevention and treatment of obesity of the present invention preferably includes a black rice biotransformation product and may additionally include mustard leaf extract or green tea extract. Preferably, it includes a black rice biotransformation product and a green tea extract, but is not limited thereto.

[0069]

[0070] According to another aspect of the present invention, the present invention provides a use of a pharmaceutical composition comprising a black rice bioconversion product fermented with basidiomycete mycelia for the prevention or treatment of obesity.

[0071] The above obesity refers to a condition in which abnormal or excessive fat is accumulated in adipose tissue.

[0072] The above-mentioned black rice bran bioconversion product fermented with basidiomycete mycelia is a bioconversion product manufactured by a method including: (a) a step of converting black rice bran into a liquid culture medium; (b) a step of inoculating basidiomycete mycelia into the liquid black rice bran culture medium of step (a) and performing culture fermentation; and (c) a step of treating the fermented product of step (b) with a cellulolytic enzyme.

[0073] The pharmaceutical composition administered for the prevention and treatment of obesity of the present invention preferably includes a black rice biotransformation product and may additionally include mustard leaf extract or green tea extract. Preferably, it includes a black rice biotransformation product and a green tea extract, but is not limited thereto.

[0074]

[0075] The composition comprising the black rice bioconversion product of the present invention as an active ingredient has been shown to be harmless to the human body as a natural food-derived substance and to have excellent anti-obesity efficacy. Therefore, the black rice bioconversion product of the present invention is expected to find significant use in the health, medical, and food fields as a composition that can be administered alone or in combination with other natural food-derived substances.

[0076]

[0077] Figure 1 is a schematic diagram showing the manufacturing process of black rice bioconversion product or freeze-dried powder thereof.

[0078] Figure 2 is a schematic diagram showing the schedule for preparing an animal model and administering an effective ingredient to evaluate the anti-obesity activity of a composition containing a black rice bioconversion product.

[0079] Figure 3 shows the results of analyzing the average daily intake of each group of mice during the above animal test.

[0080] Figure 4 shows the results of tracking the weekly weight change of each group of mice during the above animal test.

[0081] Figure 5 shows the results of histological observation of abdominal fat collected from the tested animals.

[0082] Figure 6 shows the results of confirming the effect of adding mustard extract or green tea extract to the high-liquid fraction of black rice bioconversion product, as measured by mouse body weight.

[0083] Figure 7 shows the results of confirming the effect of adding mustard extract or green tea extract to the high-liquid fraction of black rice bioconversion product in terms of the amount of white adipose tissue.

[0084] Figure 8 shows the results of confirming the effect on the size of fat cells when additionally using mustard extract or green tea extract in combination with the high-liquid separation fraction of black rice bioconversion product.

[0085] Figure 9 shows the results of histologically confirming the difference in fat cell size when mustard extract or green tea extract was used in combination with the high-liquid fraction of black rice bioconversion product.

[0086] Figure 10 shows the results of confirming the effect on blood sugar levels when additionally using mustard extract or green tea extract in combination with the high-liquid fraction of black rice bioconversion product.

[0087] Figure 11 shows the results of confirming the effect of using mustard extract or green tea extract in combination with the high-liquid fraction of black rice bioconversion product on neutral fat or total cholesterol levels.

[0088] Figure 12 shows the results of confirming the effect of adding mustard extract or green tea extract to the high-liquid fraction of black rice bioconversion product in terms of high-density cholesterol and low-density cholesterol levels.

[0089] Figure 13 shows the results of confirming the effect of using mustard extract or green tea extract in combination with the high-liquid fraction of black rice bioconversion product, as measured by GOT / GPT levels, which are indicators of liver damage.

[0090] Figure 14 shows the results of confirming the effect of using mustard extract or green tea extract in combination with the high-liquid fraction of black rice bioconversion product through histological changes in mouse liver tissue.

[0091]

[0092] After measuring the body weight of each group of mice after 8 weeks of diet, the mustard leaf extract on its own showed a very superior weight loss effect compared to HFD only (positive control group). On the other hand, BRB-FS and green tea extract showed a very minimal weight loss effect at the dosages used in this example, but when BRB-FS and green tea extract were administered together, the weight loss effect was significantly increased, whereas when BRB-FS and mustard leaf extract were administered together, a conflicting effect occurred and the weight loss effect was significantly eliminated (disappeared). This means that not all plant extracts known to have a weight loss effect of each ingredient always show a synergistic effect when used together, and rather, a conflicting effect may occur.

[0093]

[0094] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0095]

[0096] Example 1. Bioconversion process of fermentation and enzyme treatment

[0097] Example 1-1. Black rice pretreatment and black rice bran production

[0098] In order to perform the preprocessing from the purchased raw black rice to the milling process to obtain black rice bran, the mold contamination level of the raw material was measured, and then a washing process was performed to remove foreign substances and contaminants from the black rice raw material. The washing process was performed in three steps: ① an air washing step to remove foreign substances and mold spores, ② a water washing step to remove residual pesticides, and ③ an alcohol (Et-OH) washing step to remove microbial contamination. The raw material that completed the washing process was dried in a hot air dryer capable of mass drying, and then went through a milling process to obtain black rice bran.

[0099]

[0100] Example 1-2. Obtaining fermented black rice bran (BRB-F)

[0101] Black rice bran powder, from which foreign matter and mold contamination had been removed, was treated with enzymes and heat-treated to make a liquid culture medium, after which water was added. Commercially available enzyme product, amylase series, fungamyl 800L alpha-amylase (derived from Aspergillus oryzae), a hydrolase, was used. After adding 0.02% of the enzyme, the temperature was maintained at around 50°C and pH 4-6, and the reaction was carried out for 1 hour, followed by sterilization at high temperature for 30 minutes to make a culture (fermentation) medium for black rice bran. Afterwards, shiitake mushroom mycelia, which were separately cultured as basidiomycetes, were added to the culture (fermentation) medium. The fermentation process of the bioconversion process was performed by inoculating 10% (v / v) of the basidiomycete mycelial culture and culturing for 3 to 5 days at 28 to 30 ℃ and pH 4.5 to 7 to obtain a fermented product. The basidiomycete mycelia can be selected from the mycelia of medicinal and edible basidiomycetes such as shiitake mushrooms, phellodendron mushrooms, chaga mushrooms, maitake mushrooms, oyster mushrooms, pine mushrooms, and chive mushrooms, but shiitake mushroom mycelia are preferred and have been confirmed to have the same effect. In addition, these basidiomycete mycelia can be used by receiving strains from institutions such as the Korea Center for Microorganism Conservation (KCCM), Korea Center for Biotechnology and Biotechnology (KCTC), Korea Cell Line Bank (KCLB), Korea Agricultural Microorganism Resource Center (KACC), and the American Type Culture Collection (ATCC).

[0102] The enzymatic treatment of the bioconversion process for the above fermented product used cellulase, a cellulose-decomposing enzyme. Cellulase can be used alone, or a commercially available enzyme product containing various enzymes, such as cellulase, hemicellulase, pectinase, and glucanase, can be used. In this case, the enzyme was added in an appropriate amount (the optimal amount indicated in the product description for each enzyme). As for the enzyme, one or more of commercially available enzymes, such as Laminex (a complex derived from Tricoderma reesei), Viscozyme (a complex derived from Aspergillus), Cellulase (a complex derived from Aspergillus niger), Filtrase (a complex derived from Tricoderma reesei), Rapidase (a complex derived from Aspergillus niger), and Sumizyme (a complex containing pectinase derived from Aspergillus niger), may be selected and used, but Laminex is preferred, and its effect has been confirmed to be the same. The enzyme / substrate reaction was performed by adding the recommended concentration (0.05%) presented in the product description of Laminex enzyme and rotating at 250 rpm for 1 to 3 hours at 50 to 60°C. BRB-F (fermented black rice bran) produced by the bioconversion process was subjected to an enzyme inactivation process and a sterilization process at 90°C for 1 hour, and then freeze-dried to obtain BRB-F (fermented black rice bran powder) (Fig. 1).

[0103]

[0104] Example 1-3. Obtaining a solid-liquid fraction (BRB-FS) of fermented black rice bran

[0105] The black rice fermented product produced by the bioconversion process of fermentation and enzyme treatment was subjected to an enzyme inactivation process and a sterilization process at 90℃ for 1 hour, and then freeze-dried and powdered. In addition, the powder of the black rice fermented product having the immune-activating effect is dissolved in 20 times the amount of water, or the black rice fermented product fermentation liquid is centrifuged or passed through a filter to remove insoluble residues to obtain a solid-liquid separation fraction (BRB-F solid-liquid separation fraction, or BRB-FS), or this can be freeze-dried to obtain a powder. More specifically, the method for producing the solid-liquid separation fraction is performed by centrifuging or filtration to remove insoluble residues contained in the solution of the black rice fermented product powder or the black rice fermented product fermentation liquid. That is, to remove insoluble residues, centrifugation was performed at 10,000 rpm for 30 minutes or passing the product through a filter with a pore size of 200 mesh (approximately 75 μm) and 1 μm. In small-scale production, centrifugation is convenient, but in large-scale production, using a filter is preferable. The above fraction or powder refers to the bioconverted product.

[0106]

[0107] Example 2. Evaluation of the anti-obesity effect of black rice biotransformation products.

[0108] To evaluate the anti-obesity effect of black rice bran bioconversion product, 6-week-old female BALB / c mice were purchased from Orient Bio (Seongnam, Korea) and maintained at an indoor temperature of 22±2℃ until use in the experiment, with sufficient water and food supplied. Mouse groups were established as shown in Table 1 below, and the mice were randomly divided into groups of 10. After a 1-week adaptation diet, they were fed a high-fat diet containing 60% fat (D12492, 60% fat) for 8 to 10 weeks to induce obesity and fatty liver formation (Fig. 2). The black rice bran bioconversion product manufactured in Example 1 was administered together with the high-fat diet, and body weight and food intake were measured once a week. The average daily intake and body weight changes of the mice during the test are shown in Figs. 3 and 4.

[0109]

[0110] As a result of the test, both the high-fat diet (positive control) group and the BRB-F solid-liquid fraction group had lower average intakes than the normal diet (negative control) group, but there was no significant difference between the high-fat diet (positive control) group and the BRB-F solid-liquid fraction group (Fig. 3). On the other hand, despite similar daily intakes, the high-fat diet (positive control) group showed significant weight gain after 10 weeks compared to the BRB-F solid-liquid fraction group. These results showed that administration of the BRB-F solid-liquid fraction had an excellent effect on weight loss (Fig. 4).

[0111] The above mice were sacrificed by CO2 inhalation, and abdominal fat was collected and observed histologically. As a result, abdominal fat was found to be over-accumulated in the high-fat diet group, BRB-F high-liquid fractionation group, and normal diet group in that order. In particular, the size of fat cells in the high-fat diet group was found to be significantly larger (Fig. 5).

[0112]

[0113] Example 3. Preparation of fresh or green tea extract

[0114] A mixture of purified water and ethanol (ethanol concentration: 60%) corresponding to 30 parts by weight of the dried raw material of mustard (Brassica juncea) was added, and hot water extraction was performed at 70℃ for 3 hours. Thereafter, the extract was filtered through a 1.0 μm sieve and then sterilized through a 0.2 μm sieve. When high-frequency extraction was used instead of hot water extraction, 30-100 parts by weight of the dried raw material was added to a mixture of purified water and ethanol (ethanol concentration: 0-60%), and this was subjected to high-frequency extraction at room temperature. The high-frequency extraction was performed by treating the mixture at a frequency of 900 to 1000 kHz (970 kHz) or at a power of 200 to 400 W for 2-4 hours. Thereafter, the extract was filtered through a 1.0 μm sieve and then sterilized through a 0.2 μm sieve. The extract was used in liquid form, or lyophilized and used in powder form.

[0115] In addition, 10-15 parts by weight of dried raw material of green tea (Camellia sinensis) was added to a mixed solvent of purified water and propanediol (propanediol concentration: 10-30%), and hot water extraction was performed at 60-70℃ for 14-20 hours. Thereafter, the extract was filtered through 0.45 μm and then sterilized through 0.2 μm. When high-frequency extraction was used instead of hot water extraction, 10-15 parts by weight of dried raw material was added to a mixed solvent of purified water and propanediol (propanediol concentration: 10-30%), and high-frequency extraction was performed at room temperature. The high-frequency extraction was performed by treating the mixture at a frequency of 900 to 1000 kHz (970 kHz) or a power of 200 to 400 W for 2-4 hours. Afterwards, the extract was filtered through a 0.45 μm sieve and then through a 0.2 μm sieve. The extract was used in liquid form or lyophilized and used in powder form.

[0116]

[0117] Example 4. Evaluation of the anti-obesity effects of black rice bran bioconversion product high-liquid fraction and mustard / green tea extracts.

[0118] To evaluate the anti-obesity effects of the high-liquid fraction of black rice bioconversion product and mustard leaf extract, or the high-liquid fraction of black rice bioconversion product and green tea extract, animal experiments were conducted using the same method as in Example 2. The groups were set as shown in Table 2 below.

[0119]

[0120] After measuring the body weight of each group of mice after 8 weeks of diet, the mustard leaf extract itself showed a very excellent weight loss effect compared to HFD only (positive control group). On the other hand, BRB-FS and green tea extract showed a very minimal weight loss effect at the dosages used in this example, but when BRB-FS and green tea extract were administered together, the weight loss effect was significantly increased, whereas when BRB-FS and mustard leaf extract were administered together, a conflicting effect occurred and the weight loss effect was greatly eliminated (disappeared) (Fig. 6).

[0121] The above mice were sacrificed by CO2 inhalation, and the abdominal fat (white adipose tissue) was collected to measure the weight and size of adipocytes. As a result, the weight of white adipose tissue (WAT) and the average diameter of adipocytes also showed a similar pattern to the above body weight results (Figs. 7 to 9). In particular, in the case of mustard extract, it was found that the higher the administered concentration, the more conflicting effects with BRB-FS appeared, and the effect of reducing the weight of white adipose tissue and the average diameter of adipocytes was significantly reduced.

[0122] Immediately after sacrifice of the mice, blood was collected from the heart, coagulation was induced at 4°C for 30 minutes, and serum was separated by centrifugation at 3,000 g for 30 minutes. Blood glucose in the serum was measured using a blood glucose meter (ACCU-CECK, Roche), the amount of triglyceride was measured using an enzymatic assay kit (Wako, Osaka, Japan), the amounts of total cholesterol, high-density cholesterol, and low-density cholesterol were measured using a cholesterol detection kit (total cholesterol detection kit, Asan Pharmaceuticals, Seoul, Korea), and the amount of GOT / GPT (glutamate oxaloacetate transaminase / glutamate pyruvate transaminase), which is an indicator of liver damage in the serum, was measured using a GOT / GPT assay kit (GOT / GPT assay kit, Asan Pharmaceuticals, Seoul, Korea). In all biochemical analyses, the components related to obesity were similar to the above body weight and white fat results. When BRB-FS and green tea extract were used together, a synergistic effect was observed, and the blood sugar, triglyceride, total cholesterol, high-density cholesterol, low-density cholesterol, and GOT and GPT, which are liver damage indicators, were significantly reduced. On the other hand, when BRB-FS and mustard leaf extract were used together, a conflicting effect was observed, and the reduced values ​​were greatly increased again, and the reduction effect was largely eliminated (disappeared) (Figs. 10 to 13).

[0123] Immediately after the sacrifice of the above mice, liver tissues were obtained and the morphology of the liver tissue was confirmed by H&E (Hematoxylin and eosin) staining. As a result of the test, compared to the normal diet (negative control group) in which the shape of the hepatocytes and the boundaries between cells were clear, the morphology of the cells and the boundaries between cells were unclear in the case of the high-fat diet. When mustard leaf extract or green tea extract was administered alone to the high-fat diet, the morphology of the hepatocytes was significantly clearer when the mustard leaf extract was administered than when the green tea extract was administered alone. However, when BRB-FS was additionally administered together, the morphology of the hepatocytes in the green tea extract + BRB-FS administration group became clearer, whereas the morphology of the hepatocytes in the mustard leaf extract + BRB-FS administration group became unclear.

[0124] In summary, these results imply that not all plant extracts known to have weight loss effects of each ingredient always produce a synergistic effect when used together, and that even a conflicting effect may occur.

[0125]

[0126] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0127]

[0128] The black rice bioconversion product of the present invention is a composition that can be administered alone or in combination with other natural food-derived substances, and is expected to be widely used in the health, medical, and food fields.

Claims

1. A pharmaceutical composition for preventing or treating obesity, comprising a black rice bioconversion product fermented with basidiomycete mycelia as an active ingredient.

2. In paragraph 1, The bioconversion product of black rice bran fermented with basidiomycete mycelia is (a) A step of converting black rice bran into a liquid culture medium; (b) a step of inoculating basidiomycete mycelia into the liquid black rice medium cultured in step (a) and performing culture fermentation; and (c) A pharmaceutical composition manufactured by a method including a step of treating the fermented product of step (b) with a cellulolytic enzyme.

3. In paragraph 2, A pharmaceutical composition wherein the above basidiomycete mycelia are at least one mycelia selected from the group consisting of shiitake mushrooms, chanterelle mushrooms, chaga mushrooms, leaf mushrooms, wood ear mushrooms, snow mushrooms, and chive mushrooms.

4. In paragraph 2, A pharmaceutical composition, wherein the above-mentioned cellulolytic enzyme is at least one selected from the group consisting of cellulase, hemicellulase, pectinase, and glucanase.

5. In paragraph 2, The above pharmaceutical composition, (d) A pharmaceutical composition manufactured by a method further comprising a step of removing insoluble residue from the fermented product of step (c).

6. In paragraph 1, A pharmaceutical composition, wherein the pharmaceutical composition further comprises a green tea extract.

7. In paragraph 6, A pharmaceutical composition wherein the above extract is a hot water extract or a high-frequency extract.

8. A food composition for preventing or improving obesity, comprising a black rice bioconversion product fermented with basidiomycete mycelia as an active ingredient.

9. In paragraph 8, A food composition, wherein the food composition further comprises a green tea extract.

10. In paragraph 8, The food composition is manufactured in the form of a beverage, gum, tea, vitamin complex, powder, granules, tablets, capsules, jelly, gel, confectionery, rice cake, or bread.

11. A cosmetic composition for preventing or improving obesity, comprising as an active ingredient a bioconversion product obtained by fermenting black rice bran with basidiomycete mycelia.

12. In paragraph 11, A cosmetic composition, wherein the cosmetic composition further comprises a green tea extract.

13. In paragraph 11, The above cosmetic composition is a cosmetic composition manufactured in the form of a toner, a nutritional lotion, a nutritional essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, a baby powder, a shower gel, a shower cream, a sunscreen lotion, a sunscreen cream, a suntan cream, a skin lotion, a skin cream, a UV-blocking cosmetic, a cleansing milk, a depilatory agent {for cosmetic use}, a face and body lotion, a face and body cream, a skin whitening cream, a hand lotion, a hair lotion, a cosmetic cream, jasmine oil, a bath soap, a liquid soap, a beauty soap, a shampoo, a hand sanitizer, a medicated soap {for non-medical use}, a cream soap, a facial wash, a hair rinse, a cosmetic soap, a tooth whitening gel, or a toothpaste. 14.(a) A step for producing a black rice bioconversion product; and, (b) A method for producing a pharmaceutical composition for preventing or treating obesity, comprising the step of mixing a green tea extract into (a). 15.(a) A step for producing a black rice bioconversion product; and, (b) A method for producing a food composition for preventing or improving obesity, comprising the step of mixing a green tea extract into (a). 16.(a) A step for producing a black rice bioconversion product; and, (b) A method for producing a cosmetic composition for preventing or improving obesity, comprising the step of mixing a green tea extract into (a).

17. A method for preventing or treating obesity, comprising the step of administering to a subject a pharmaceutical composition containing a bioconversion product of black rice bran fermented with basidiomycete mycelia.

18. In paragraph 18, A method wherein the pharmaceutical composition further comprises a green tea extract.

19. Use of a pharmaceutical composition containing a bioconversion product of black rice bran fermented with basidiomycete mycelia for the prevention or treatment of obesity.

20. In paragraph 20, The above pharmaceutical composition further comprises a green tea extract.

Images